Treatment of patients with severe glucocorticoid-refractory ulcerative colitis: Cyclosporine or infliximab?;Behandeling van patiënten met ernstige glucocorticoïd-refractaire colitis ulcerosa: Ciclosporine of infliximab?

Nederlands Tijdschrift voor Geneeskunde

Volumn 157, Issue 45, 2013, Pages

  Löwenberg, Mark ^a   De Boer, Nanne K H ^b   Dewint, Pieter ^c   Hoentjen, Frank ^d  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; GLUCOCORTICOID; INFLIXIMAB; MONOCLONAL ANTIBODY;

ARTICLE; DRUG EFFICACY; HUMAN; POSTOPERATIVE COMPLICATION; PREOPERATIVE TREATMENT; ULCERATIVE COLITIS; COLON RESECTION; REVIEW; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; COLECTOMY; COLITIS, ULCERATIVE; CYCLOSPORINE; GLUCOCORTICOIDS; HUMANS; POSTOPERATIVE COMPLICATIONS; TREATMENT OUTCOME;

EID: 84891330361     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Dinesen LC, Walsh AJ, Protic MN, et al. The pattern and outcome of acute severe colitis. J Crohn's Colitis. 2010;4:431-7.
2. Edwards FC, Truelove SC. The course and prognosis of ulcerative colitis. Gut. 1963;4:299-315.
3. Dignass A, Lindsay JO, Sturm A, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. J Crohn's Colitis. 2012;6:991-1030.
4. Dignass A, Eliakim R, Magro F, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosis. J Crohn's Colitis. 2012;6:965-90.
5. Weersma RK, van Dullemen HM, Kleibeuker JH, Ploeg RJ, Dijkstra G. De behandeling van ernstige colitis ulcerosa. Ned Tijdschr Geneeskd. 2006;150:12-17.
6. Lichtiger S, Present DH, Kornbluth A, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med. 1994;330:1841-5.
7. D'Haens G, Lemmens L, Geboes K, et al. Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis. Gastroenterology. 2001;120:1323-9.
8. Van Assche AG, D'Haens G, Noman M, et al. Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis. Gastroenterology. 2003;125:1025-31.
9. Papadakis KA, Tung JK, Binder SW, et al. Outcome of cytomegalovirus infections in patients with inflammatory bowel disease. Am J Gastroenterol. 2001;96:2137-42.
10. Gornet JM, Couve S, Hassani Z, et al. Infliximab for refractory ulcerative colitis or indeterminate colitis: an open-label multicentre study. Aliment Pharmacol Ther. 2003;18:175-81.
11. Kohn A, Daperno M, Armuzzi A, et al. Infliximab in severe ulcerative colitis: short-term results of different infusion regimens and long-term follow-up. Aliment Pharmacol Ther. 2007;26:747-56.
12. Järnerot G, Hertervig E, Friis-Liby I, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology. 2005;128:1805-11.
13. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353:2462-76.
14. Oussalah A, Evesque L, Laharie D, et al. A multicenter experience with infliximab for ulcerative colitis: outcomes and predictors of response, optimization, colectomy, and hospitalization. Am J Gastroenterol. 2010;105:2617-25.
15. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. 2010;362:1383-95.
16. Laharie D, Bourreille A, Branche J, et al. Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. Lancet. 2012;380:1909-15.
17. Leblanc S, Allez M, Seksik P, et al. Successive treatment with cyclosporine and infliximab in steroid-refractory ulcerative colitis. Am J Gastroenterol. 2011;106:771-7.
18. Travis SP, Farrant JM, Ricketts C, et al. Predicting outcome in severe ulcerative colitis. Gut. 1996;38:905-10.
19. Turner D, Walsh CM, Steinhart AH, Griffiths AM. Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression. Clin Gastroenterol Hepatol. 2007;5:103-10.
20. Bartels SA, Vlug MS, Henneman D, Ponsioen CY, Tanis PJ, Bemelman WA. Less adhesiolysis and hernia repair during completion proctocolectomy after laparoscopic emergency colectomy for ulcerative colitis. Surg Endosc. 2012;26:368-73.
21. Hyde GM, Jewell DP, Kettlewell MG, Mortensen NJ. Cyclosporin for severe ulcerative colitis does not increase the rate of perioperative complications. Dis Colon Rectum. 2001;44:1436-40.
22. Yang Z, Wu Q, Wang F, Wu K, Fan D. Meta-analysis: effect of preoperative infliximab use on early postoperative complications in patients with ulcerative colitis undergoing abdominal surgery. Aliment Pharmacol Ther. 2012;36:922-8.